Home>Topics>Companies>Quest Diagnostics

Quest Diagnostics DGX

  1. All
  2. Commentary
  3. Headlines
    1. LabCorp Plans for Covance Acquisition; Our Fair Value Estimate Stands

      Commentary

      Mon, 3 Nov 2014

      for the combined company. However, we believe the combined entity will enjoy competitive benefits over key rival Quest Diagnostics , especially over the longer term as the new post-health-care-reform world evolves. We think the strategic

    2. Quest Sees Signs of Improving Business in Third Quarter

      Commentary

      Thu, 23 Oct 2014

      Quest Diagnostics posted respectable third-quarter results ..... suggest volume and pricing are improving for Quest . We stand behind the firm's narrow ..... the moat trend is stable. We applaud Quest 's decision to walk away from unprofitable

    3. Quest Sees Slight Volume Gain in Second Quarter, but Also Faces Price Decline

      Commentary

      Thu, 24 Jul 2014

      Quest Diagnostics released second-quarter performance ..... organic volume growth remains lackluster at Quest . On one hand, quarterly organic volume ..... quarters of declines. On the other hand, Quest continues to trail its main rival LabCorp

    4. Raising Fair Value on Sonic Healthcare to Reflect Growing Offshore Presence

      Commentary

      Wed, 11 Jun 2014

      are reimbursed under Medicare and Medicaid respectively. In the U.S., Sonic remains a minnow compared with Quest Diagnostics and LabCorp, with a market share of about 1.5% versus 15%. The U.S. market remains attractive given expected

    5. Top 10 Purchases and Sales from Our Ultimate Stock-Pickers

      Headlines

      Tue, 3 Jun 2014

      was with Oakmark Equity & Income's elimination of Quest Diagnostics DGX "> DGX . Clyde McGregor noted the following in his ..... and three that didn’t (Encana, Hospira and Quest Diagnostics )... In the case of Encana and Quest Diagnostics

    6. LabCorp's First-Quarter Volume Was Solid, but Pricing Took a Hit

      Commentary

      Mon, 28 Apr 2014

      molecular pathology codes and sequestration. As with Quest Diagnostics , we anticipate the pressure should lift somewhat now ..... believe this sets LabCorp apart from its largest rival Quest . LabCorp is on the cusp of rolling out its Beacon LBS

    7. Quest Diagnostics Posts Anemic 1Q, and Our Fair Value Estimate Is Unchanged

      Commentary

      Thu, 24 Apr 2014

      Quest Diagnostics posted tepid first-quarter performance ..... the quarter to change our thinking on Quest 's narrow economic moat. Although the ..... these slightly more positive trends, Quest 's operating margin fell yet again

    8. Oakmark Equity and Income Fund Letter to Shareholders

      Headlines

      Tue, 8 Apr 2014

      t (Encana, Hospira and Quest Diagnostics ). Cimarex and Concho are ..... position. In the case of Encana and Quest Diagnostics , fundamental underperformance ..... redeploy the money elsewhere. With Quest , its weakening market

    9. Myriad Settles Patent Infringement Lawsuit with Gene by Gene

      Commentary

      Fri, 7 Feb 2014

      revealed in the remaining patent infringement cases it is involved in. These include lawsuits with Ambry Genetics, Quest Diagnostics , and LabCorp, all of which have greater resources at their disposal than Gene by Gene, in our opinion.

    10. Quest Diagnostics Posts Another Quarter of Lackluster Results

      Commentary

      Thu, 30 Jan 2014

      Quest Diagnostics posted another quarter of tepid performance ..... yet to see substantial improvement in Quest 's operations that translates into greater ..... However, as we have noted before, Quest 's narrow moat remains solid, as it

    « Prev12345Next »
    Content Partners